While all the drugs reduced blood sugar levels, dipeptidyl peptidase 4 (DPP-4) inhibitors among sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists did not reduce mortality risk, finds a new study. The findings of this study are published in the journal of JAMA.